JPWO2023009498A5 - - Google Patents

Info

Publication number
JPWO2023009498A5
JPWO2023009498A5 JP2024504840A JP2024504840A JPWO2023009498A5 JP WO2023009498 A5 JPWO2023009498 A5 JP WO2023009498A5 JP 2024504840 A JP2024504840 A JP 2024504840A JP 2024504840 A JP2024504840 A JP 2024504840A JP WO2023009498 A5 JPWO2023009498 A5 JP WO2023009498A5
Authority
JP
Japan
Prior art keywords
fragment
antibody
cells
klrg1
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024504840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528877A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/038310 external-priority patent/WO2023009498A1/en
Publication of JP2024528877A publication Critical patent/JP2024528877A/ja
Publication of JPWO2023009498A5 publication Critical patent/JPWO2023009498A5/ja
Pending legal-status Critical Current

Links

JP2024504840A 2021-07-26 2022-07-26 キラー細胞レクチン様受容体サブファミリーgメンバー1(klrg1)枯渇性抗体 Pending JP2024528877A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163225828P 2021-07-26 2021-07-26
US63/225,828 2021-07-26
US202263308222P 2022-02-09 2022-02-09
US63/308,222 2022-02-09
PCT/US2022/038310 WO2023009498A1 (en) 2021-07-26 2022-07-26 Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Publications (2)

Publication Number Publication Date
JP2024528877A JP2024528877A (ja) 2024-08-01
JPWO2023009498A5 true JPWO2023009498A5 (enrdf_load_stackoverflow) 2025-08-04

Family

ID=85087207

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024504840A Pending JP2024528877A (ja) 2021-07-26 2022-07-26 キラー細胞レクチン様受容体サブファミリーgメンバー1(klrg1)枯渇性抗体

Country Status (7)

Country Link
US (1) US20250101112A1 (enrdf_load_stackoverflow)
EP (1) EP4377346A1 (enrdf_load_stackoverflow)
JP (1) JP2024528877A (enrdf_load_stackoverflow)
AU (1) AU2022320627A1 (enrdf_load_stackoverflow)
CA (1) CA3227742A1 (enrdf_load_stackoverflow)
MX (1) MX2024001277A (enrdf_load_stackoverflow)
WO (1) WO2023009498A1 (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
DK2792236T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
CN110300598A (zh) 2016-09-16 2019-10-01 布里格姆妇女医院有限公司 Klrg1消耗治疗
US20210002373A1 (en) * 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
SG11202110610VA (en) * 2019-04-09 2021-10-28 Abcuro Inc Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Similar Documents

Publication Publication Date Title
RU2563830C2 (ru) Лечение остеоартрита и боли
CN106554417B (zh) 抗ox40抗体和使用其的方法
JP2023123627A5 (enrdf_load_stackoverflow)
RU2019134352A (ru) Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
JP2020528768A5 (enrdf_load_stackoverflow)
RU2013155906A (ru) Антитела анти-angptl3 и их применение
JP2011506483A5 (enrdf_load_stackoverflow)
RU2008149918A (ru) Антитела к nkg2a и их применения
RU2009136913A (ru) Биспецифические связывающие агенты с межвидовой специфичностью
RU2012119788A (ru) Связывающие il-1 белки
KR20110110349A (ko) Il-1 결합 단백질
JPWO2019246514A5 (enrdf_load_stackoverflow)
CN109999195A (zh) 类风湿关节炎的治疗
JP2024024114A5 (enrdf_load_stackoverflow)
JPWO2020132066A5 (enrdf_load_stackoverflow)
WO2013140787A1 (ja) 特発性炎症性筋疾患の予防又は治療剤
JPWO2020113194A5 (enrdf_load_stackoverflow)
TW202340259A (zh) 抗cd19藥劑之劑量方案及其用途
JP2018533588A (ja) 治療パラダイム
JPWO2019246356A5 (enrdf_load_stackoverflow)
CN114786723A (zh) 序贯抗cd19疗法
JPWO2020210512A5 (enrdf_load_stackoverflow)
JPWO2023009498A5 (enrdf_load_stackoverflow)
JPWO2021163389A5 (enrdf_load_stackoverflow)
JPWO2020172475A5 (enrdf_load_stackoverflow)